A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors.
- Author:
Shuai-nan LIU
1
;
Zhu-fang SHEN
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Publication Type:Journal Article
- MeSH:
Alzheimer Disease;
drug therapy;
enzymology;
Animals;
Blood Glucose;
metabolism;
Diabetes Mellitus;
drug therapy;
enzymology;
Enzyme Inhibitors;
therapeutic use;
Glycogen;
metabolism;
Glycogen Synthase Kinase 3;
antagonists & inhibitors;
metabolism;
physiology;
Humans;
Insulin;
metabolism;
Insulin Resistance;
Signal Transduction
- From:
Acta Pharmaceutica Sinica
2007;42(12):1227-1231
- CountryChina
- Language:Chinese
-
Abstract:
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase, originally identified as a protein kinase by its ability to phosphorylate and inactivate glycogen synthase. It was found that the overexpression of GSK-3 is associated with some diseases, such as diabetes, Alzheimer disease and other neurodegenerative diseases. Some pharmacological inhibitors of GSK-3 have been demonstrated to mimic insulin signaling, adjust glycogen synthesis and glucose metabolism, and improve insulin resistance. So GSK-3 inhibitors are realized as a new approach of treating diabetes. This review summarizes current advances in research of GSK-3 inhibitors as a new therapeutic approach for diabetes.
